Charles River Laboratories International (CRL) Competitors

$156.85 +0.82 (+0.53%)

As of 01:10 PM Eastern

CRL vs. TECH, A, IQV, RVTY, and TMO

Should you buy Charles River Laboratories International stock or one of its competitors? MarketBeat compares Charles River Laboratories International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Charles River Laboratories International include Bio-Techne (TECH), Agilent Technologies (A), IQVIA (IQV), Revvity (RVTY), and Thermo Fisher Scientific (TMO). These companies are all part of the "medical" sector.

How does Charles River Laboratories International compare to Bio-Techne?

Charles River Laboratories International (NYSE:CRL) and Bio-Techne (NASDAQ:TECH) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

In the previous week, Bio-Techne had 3 more articles in the media than Charles River Laboratories International. MarketBeat recorded 3 mentions for Bio-Techne and 0 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 1.00 beat Bio-Techne's score of 0.68 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Overall Sentiment
Charles River Laboratories International	Positive
Bio-Techne	Positive

98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by insiders. Comparatively, 1.3% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bio-Techne has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	1.88	-$144.34M	-$3.76	N/A
Bio-Techne	$1.22B	5.98	$73.40M	$0.69	67.55

Charles River Laboratories International has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

Charles River Laboratories International presently has a consensus price target of $205.86, suggesting a potential upside of 31.21%. Bio-Techne has a consensus price target of $65.92, suggesting a potential upside of 41.44%. Given Bio-Techne's stronger consensus rating and higher possible upside, analysts clearly believe Bio-Techne is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79

Bio-Techne has a net margin of 9.05% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-4.59%	15.36%	6.61%
Bio-Techne	9.05%	13.57%	10.66%

Summary

Bio-Techne beats Charles River Laboratories International on 11 of the 16 factors compared between the two stocks.

How does Charles River Laboratories International compare to Agilent Technologies?

Charles River Laboratories International (NYSE:CRL) and Agilent Technologies (NYSE:A) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Charles River Laboratories International has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

In the previous week, Agilent Technologies had 11 more articles in the media than Charles River Laboratories International. MarketBeat recorded 11 mentions for Agilent Technologies and 0 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 1.00 beat Agilent Technologies' score of 0.32 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Overall Sentiment
Charles River Laboratories International	Positive
Agilent Technologies	Neutral

Agilent Technologies has a net margin of 18.26% compared to Charles River Laboratories International's net margin of -4.59%. Agilent Technologies' return on equity of 24.49% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-4.59%	15.36%	6.61%
Agilent Technologies	18.26%	24.49%	12.83%

98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Charles River Laboratories International presently has a consensus target price of $205.86, indicating a potential upside of 31.21%. Agilent Technologies has a consensus target price of $163.71, indicating a potential upside of 44.34%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Agilent Technologies is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63
Agilent Technologies	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Agilent Technologies has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	1.88	-$144.34M	-$3.76	N/A
Agilent Technologies	$6.95B	4.61	$1.30B	$4.53	25.04

Summary

Agilent Technologies beats Charles River Laboratories International on 12 of the 16 factors compared between the two stocks.

How does Charles River Laboratories International compare to IQVIA?

Charles River Laboratories International (NYSE:CRL) and IQVIA (NYSE:IQV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Charles River Laboratories International currently has a consensus price target of $205.86, suggesting a potential upside of 31.21%. IQVIA has a consensus price target of $225.69, suggesting a potential upside of 33.12%. Given IQVIA's stronger consensus rating and higher possible upside, analysts clearly believe IQVIA is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63
IQVIA	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, IQVIA had 7 more articles in the media than Charles River Laboratories International. MarketBeat recorded 7 mentions for IQVIA and 0 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 1.00 beat IQVIA's score of 0.40 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Overall Sentiment
Charles River Laboratories International	Positive
IQVIA	Neutral

Charles River Laboratories International has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Comparatively, 1.7% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

IQVIA has a net margin of 8.33% compared to Charles River Laboratories International's net margin of -4.59%. IQVIA's return on equity of 30.50% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-4.59%	15.36%	6.61%
IQVIA	8.33%	30.50%	6.53%

IQVIA has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	1.88	-$144.34M	-$3.76	N/A
IQVIA	$16.31B	1.73	$1.36B	$8.07	21.01

Summary

IQVIA beats Charles River Laboratories International on 12 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to Revvity?

Charles River Laboratories International (NYSE:CRL) and Revvity (NYSE:RVTY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

In the previous week, Revvity had 3 more articles in the media than Charles River Laboratories International. MarketBeat recorded 3 mentions for Revvity and 0 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 1.00 beat Revvity's score of 0.35 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Overall Sentiment
Charles River Laboratories International	Positive
Revvity	Neutral

Charles River Laboratories International has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Revvity has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 86.7% of Revvity shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by company insiders. Comparatively, 0.9% of Revvity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Revvity has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	1.88	-$144.34M	-$3.76	N/A
Revvity	$2.86B	3.71	$241.20M	$2.09	45.40

Revvity has a net margin of 8.26% compared to Charles River Laboratories International's net margin of -4.59%. Charles River Laboratories International's return on equity of 15.36% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-4.59%	15.36%	6.61%
Revvity	8.26%	8.00%	4.83%

Charles River Laboratories International currently has a consensus price target of $205.86, suggesting a potential upside of 31.21%. Revvity has a consensus price target of $107.73, suggesting a potential upside of 13.52%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, research analysts clearly believe Charles River Laboratories International is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63
Revvity	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.23

Summary

Charles River Laboratories International beats Revvity on 10 of the 16 factors compared between the two stocks.

How does Charles River Laboratories International compare to Thermo Fisher Scientific?

Thermo Fisher Scientific (NYSE:TMO) and Charles River Laboratories International (NYSE:CRL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Thermo Fisher Scientific presently has a consensus price target of $616.10, suggesting a potential upside of 36.96%. Charles River Laboratories International has a consensus price target of $205.86, suggesting a potential upside of 31.21%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Thermo Fisher Scientific is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96
Charles River Laboratories International	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63

Thermo Fisher Scientific has a net margin of 15.15% compared to Charles River Laboratories International's net margin of -4.59%. Thermo Fisher Scientific's return on equity of 16.86% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	15.15%	16.86%	8.15%
Charles River Laboratories International	-4.59%	15.36%	6.61%

In the previous week, Thermo Fisher Scientific had 56 more articles in the media than Charles River Laboratories International. MarketBeat recorded 56 mentions for Thermo Fisher Scientific and 0 mentions for Charles River Laboratories International. Thermo Fisher Scientific's average media sentiment score of 1.23 beat Charles River Laboratories International's score of 1.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company	Overall Sentiment
Thermo Fisher Scientific	Positive
Charles River Laboratories International	Positive

Thermo Fisher Scientific has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$44.56B	3.75	$6.70B	$18.19	24.73
Charles River Laboratories International	$4.02B	1.88	-$144.34M	-$3.76	N/A

Thermo Fisher Scientific has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Summary

Thermo Fisher Scientific beats Charles River Laboratories International on 14 of the 17 factors compared between the two stocks.

Get Charles River Laboratories International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRL vs. The Competition

Export

Metric	Charles River Laboratories International	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$7.56B	$8.21B	$6.30B	$22.90B
Dividend Yield	N/A	3.19%	2.80%	4.13%
P/E Ratio	-41.73	21.09	20.78	29.82
Price / Sales	1.88	16.26	517.98	89.10
Price / Cash	6.94	80.63	43.18	24.44
Price / Book	2.56	5.73	9.93	4.66
Net Income	-$144.34M	$180.93M	$3.54B	$1.07B
7 Day Performance	-1.35%	4.26%	-0.37%	-0.72%
1 Month Performance	-14.47%	1.16%	-0.84%	-0.61%
1 Year Performance	16.20%	2.56%	33.87%	26.96%

Charles River Laboratories International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRL Charles River Laboratories International	3.8149 of 5 stars	$156.85 +0.5%	$205.86 +31.2%	+8.9%	$7.56B	$4.02B	N/A	19,700
TECH Bio-Techne	3.9942 of 5 stars	$44.89 -5.3%	$66.77 +48.7%	-5.7%	$7.42B	$1.22B	65.06	3,100	Ex-Dividend
A Agilent Technologies	4.8671 of 5 stars	$112.80 -0.1%	$163.71 +45.1%	+0.1%	$31.91B	$6.95B	24.90	18,100	Upcoming Earnings Dividend Announcement
IQV IQVIA	4.4027 of 5 stars	$172.20 -1.6%	$225.69 +31.1%	+18.3%	$29.22B	$16.31B	21.34	93,000
RVTY Revvity	2.7255 of 5 stars	$95.01 -4.3%	$107.73 +13.4%	+1.7%	$11.10B	$2.86B	45.46	11,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CRL) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Charles River Laboratories International (CRL) Competitors

CRL vs. TECH, A, IQV, RVTY, and TMO

How does Charles River Laboratories International compare to Bio-Techne?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Summary

How does Charles River Laboratories International compare to IQVIA?

Summary

How does Charles River Laboratories International compare to Revvity?

Summary

How does Charles River Laboratories International compare to Thermo Fisher Scientific?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Charles River Laboratories International (CRL) Competitors

CRL vs. TECH, A, IQV, RVTY, and TMO

How does Charles River Laboratories International compare to Bio-Techne?

Does the media prefer CRL or TECH?

Do institutionals & insiders believe in CRL or TECH?

Which has stronger earnings and valuation, CRL or TECH?

Which has more volatility & risk, CRL or TECH?

Do analysts recommend CRL or TECH?

Is CRL or TECH more profitable?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Which has more risk and volatility, CRL or A?

Does the media refer more to CRL or A?

Is CRL or A more profitable?

Do institutionals & insiders have more ownership in CRL or A?

Do analysts rate CRL or A?

Which has stronger earnings and valuation, CRL or A?

Summary

How does Charles River Laboratories International compare to IQVIA?

Do analysts rate CRL or IQV?

Does the media favor CRL or IQV?

Which has more volatility and risk, CRL or IQV?

Do institutionals & insiders hold more shares of CRL or IQV?

Is CRL or IQV more profitable?

Which has higher valuation & earnings, CRL or IQV?

Summary

How does Charles River Laboratories International compare to Revvity?

Does the media favor CRL or RVTY?

Which has more risk & volatility, CRL or RVTY?

Do insiders and institutionals believe in CRL or RVTY?

Which has preferable valuation and earnings, CRL or RVTY?

Is CRL or RVTY more profitable?

Do analysts prefer CRL or RVTY?

Summary

How does Charles River Laboratories International compare to Thermo Fisher Scientific?

Do institutionals & insiders hold more shares of TMO or CRL?

Do analysts recommend TMO or CRL?

Is TMO or CRL more profitable?

Does the media prefer TMO or CRL?

Which has higher earnings and valuation, TMO or CRL?

Which has more volatility & risk, TMO or CRL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools